Home
INMB
INMB News

Latest INmune Bio Inc. Common stock (INMB) News on December 22, 2024

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt

GlobeNewswire

12 days ago

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt

OmniScience and INmune Bio Partner for Alzheimer’s Trial

Exec Edge

18 days ago

OmniScience and INmune Bio Partner for Alzheimer’s Trial

MT Newswires

18 days ago

INmune Bio Partners With OmniScience to Accelerate Alzheimer's Trial

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower

Business Wire

18 days ago

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

GlobeNewswire

a month ago

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)

Simply Wall St.

2 months ago

INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)

INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...

GuruFocus.com

2 months ago

INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

GlobeNewswire

2 months ago

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For

GuruFocus.com

2 months ago

INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

GlobeNewswire

2 months ago

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares

GuruFocus.com

2 months ago

Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

GlobeNewswire

2 months ago

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

GlobeNewswire

2 months ago

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

Insider Stock Buying Reaches US$951.2k On INmune Bio

Simply Wall St.

2 months ago

Insider Stock Buying Reaches US$951.2k On INmune Bio

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

GlobeNewswire

2 months ago

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs

GuruFocus.com

2 months ago

INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs

Argus Research

3 months ago

Daily – Vickers Top Buyers & Sellers for 10/01/2024

MT Newswires

3 months ago

INmune Bio Closes Enrollment for Phase 2 XPro Trial in Early Alzheimer's Disease

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease

GlobeNewswire

3 months ago

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

GlobeNewswire

3 months ago

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

MT Newswires

3 months ago

INmune Bio Says AD02 Trial for Alzheimer's Disease Reveals Strong Performance of EMACC Cognitive Measure

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

GlobeNewswire

3 months ago

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

MT Newswires

3 months ago

INmune Bio Launches $13 Million Registered Direct Offering of Common Shares, Warrants

INmune Bio Announces $13.0 Million Registered Direct Offering

GlobeNewswire

3 months ago

INmune Bio Announces $13.0 Million Registered Direct Offering

INmune Bio, Inc.'s (NASDAQ:INMB) top owners are individual investors with 44% stake, while 23% is held by institutions

Simply Wall St.

3 months ago

INmune Bio, Inc.'s (NASDAQ:INMB) top owners are individual investors with 44% stake, while 23% is held by institutions

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

GlobeNewswire

4 months ago

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

INmune Bio Second Quarter 2024 Earnings: US$0.51 loss per share (vs US$0.36 loss in 2Q 2023)

Simply Wall St.

5 months ago

INmune Bio Second Quarter 2024 Earnings: US$0.51 loss per share (vs US$0.36 loss in 2Q 2023)

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

GlobeNewswire

5 months ago

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients

GlobeNewswire

5 months ago

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

GlobeNewswire

5 months ago

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

GlobeNewswire

5 months ago

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

Shareholders Will Probably Be Cautious Of Increasing INmune Bio, Inc.'s (NASDAQ:INMB) CEO Compensation At The Moment

Simply Wall St.

5 months ago

Shareholders Will Probably Be Cautious Of Increasing INmune Bio, Inc.'s (NASDAQ:INMB) CEO Compensation At The Moment

INmune Bio’s unique Alzheimer’s trial endpoint receives validation

Clinical Trials Arena

6 months ago

INmune Bio’s unique Alzheimer’s trial endpoint receives validation

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial

GlobeNewswire

6 months ago

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial

MT Newswires

7 months ago

Sector Update: Health Care Stocks Higher in Afternoon Trading

MT Newswires

7 months ago

INmune Bio to Join Russell 3000 Index in July

INmune Bio Inc. to Join Russell 3000® Index

GlobeNewswire

7 months ago

INmune Bio Inc. to Join Russell 3000® Index

INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript

Insider Monkey

7 months ago

INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript

INmune Bio First Quarter 2024 Earnings: EPS Misses Expectations

Simply Wall St.

7 months ago

INmune Bio First Quarter 2024 Earnings: EPS Misses Expectations

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

GlobeNewswire

7 months ago

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

GlobeNewswire

8 months ago

INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

GlobeNewswire

8 months ago

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire

8 months ago

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

INmune Bio Independent Director Acquires 80% More Stock

Simply Wall St.

8 months ago

INmune Bio Independent Director Acquires 80% More Stock

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

8 months ago

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

GlobeNewswire

8 months ago

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

GlobeNewswire

8 months ago

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

GlobeNewswire

8 months ago

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript

Insider Monkey

9 months ago

INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript

INmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

9 months ago

INmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements

GuruFocus.com

9 months ago

INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

GlobeNewswire

9 months ago

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

GlobeNewswire

9 months ago

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

GlobeNewswire

9 months ago

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™

GlobeNewswire

10 months ago

INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire

10 months ago

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024

GlobeNewswire

a year ago

INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024

Insiders own 24% of INmune Bio, Inc. (NASDAQ:INMB) shares but retail investors control 53% of the company

Simply Wall St.

a year ago

Insiders own 24% of INmune Bio, Inc. (NASDAQ:INMB) shares but retail investors control 53% of the company

Clearfield (CLFD) Reports Q1 Loss, Tops Revenue Estimates

Zacks

a year ago

Clearfield (CLFD) Reports Q1 Loss, Tops Revenue Estimates

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program

GlobeNewswire

a year ago

INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program

12 Highest Rated Mattresses Under $1000

Insider Monkey

a year ago

12 Highest Rated Mattresses Under $1000

Third Coast Bancshares, Inc. (TCBX) Q4 Earnings and Revenues Top Estimates

Zacks

a year ago

Third Coast Bancshares, Inc. (TCBX) Q4 Earnings and Revenues Top Estimates

ATSG Announces New President of Airline Subsidiary ATI

Business Wire

a year ago

ATSG Announces New President of Airline Subsidiary ATI

Capital Bancorp Inc (CBNK) Reports Steady Earnings Amid Market Volatility

GuruFocus.com

a year ago

Capital Bancorp Inc (CBNK) Reports Steady Earnings Amid Market Volatility

Associated Press Finance

a year ago

Capital Bancorp: Q4 Earnings Snapshot

Virtus Diversified Income & Convertible Fund Discloses Sources of Distribution – Section 19(a) Notice

Business Wire

a year ago

Virtus Diversified Income & Convertible Fund Discloses Sources of Distribution – Section 19(a) Notice

WhiteHorse Finance, Inc. To Report Fourth Quarter 2023 and Full Year Financial Results

PR Newswire

a year ago

WhiteHorse Finance, Inc. To Report Fourth Quarter 2023 and Full Year Financial Results

Nukkleus Announces Collaboration between DRFQ and Tantel Group to Expand Footprint in Africa

Business Wire

a year ago

Nukkleus Announces Collaboration between DRFQ and Tantel Group to Expand Footprint in Africa

GDEV announces final results of previously announced self tender offer to purchase for cash a minimum of 15,000,000, up to 20,000,000 of its ordinary shares at a purchase price of $2.00 per ordinary share

GlobeNewswire

a year ago

GDEV announces final results of previously announced self tender offer to purchase for cash a minimum of 15,000,000, up to 20,000,000 of its ordinary shares at a purchase price of $2.00 per ordinary share

ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology

GlobeNewswire

a year ago

ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology

Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1

Business Wire

a year ago

Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1

Insider Sell: Chief Scientific Officer Edward Feener Sells 22,679 Shares of KalVista ...

GuruFocus.com

a year ago

Insider Sell: Chief Scientific Officer Edward Feener Sells 22,679 Shares of KalVista ...

Business Wire

a year ago

First Trust Energy Income and Growth Fund Declares its Quarterly Distribution of $0.30 Per Share

MeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisions

Zacks

a year ago

MeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisions

Euroseas Ltd. (ESEA) Soars 6.3%: Is Further Upside Left in the Stock?

Zacks

a year ago

Euroseas Ltd. (ESEA) Soars 6.3%: Is Further Upside Left in the Stock?

Getty Realty Corp. Provides 2023 Business Update

Business Wire

a year ago

Getty Realty Corp. Provides 2023 Business Update

Amicus (FOLD) Issues Preliminary Revenue Results for FY23

Zacks

a year ago

Amicus (FOLD) Issues Preliminary Revenue Results for FY23

Reuters

a year ago

UPDATE 2-Allogene to cut 22% of its workforce

Reuters

a year ago

Allogene to cut 22% of its workforce

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

GlobeNewswire

a year ago

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire

a year ago

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer

AI, taxes, real estate, healthcare: Best of 2023 theme weeks

Yahoo Finance Video

a year ago

AI, taxes, real estate, healthcare: Best of 2023 theme weeks

Unisys Wins Coveted "The Drum Award" in the B2B Rebrand or Relaunch Category

PR Newswire

a year ago

Unisys Wins Coveted "The Drum Award" in the B2B Rebrand or Relaunch Category

XOMA Declares Quarterly Preferred Stock Dividends

GlobeNewswire

a year ago

XOMA Declares Quarterly Preferred Stock Dividends

INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA

GlobeNewswire

a year ago

INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA

Peapack-Gladstone Bank’s Boonton Charity Christmas Tree Sale Supports Sound Start Foundation

GlobeNewswire

a year ago

Peapack-Gladstone Bank’s Boonton Charity Christmas Tree Sale Supports Sound Start Foundation

Unisys Revises Estimate of One-Time, Non-Cash, Pre-Tax Settlement Charge Related to Previously Announced Purchase of Group Annuity Contracts

PR Newswire

a year ago

Unisys Revises Estimate of One-Time, Non-Cash, Pre-Tax Settlement Charge Related to Previously Announced Purchase of Group Annuity Contracts

SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare Conference

GlobeNewswire

a year ago

SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare Conference

SoundThinking Expands into Latin America with Launch of ShotSpotter in Montevideo, Uruguay

GlobeNewswire

a year ago

SoundThinking Expands into Latin America with Launch of ShotSpotter in Montevideo, Uruguay

Option Care Health to Participate in the J.P. Morgan Healthcare Conference

GlobeNewswire

a year ago

Option Care Health to Participate in the J.P. Morgan Healthcare Conference

NeoGames’ Pariplay signs deal with Tipico US for further North American growth

GlobeNewswire

a year ago

NeoGames’ Pariplay signs deal with Tipico US for further North American growth

Calculating The Fair Value Of FutureFuel Corp. (NYSE:FF)

Simply Wall St.

a year ago

Calculating The Fair Value Of FutureFuel Corp. (NYSE:FF)

Thomson Reuters StreetEvents

a year ago

Q4 2023 Liquidity Services Inc Earnings Call

Liquidity Services Inc (LQDT) Reports Growth in GMV and Revenue for Q4 Fiscal Year 2023

GuruFocus.com

a year ago

Liquidity Services Inc (LQDT) Reports Growth in GMV and Revenue for Q4 Fiscal Year 2023

SoundThinking Sets Upcoming Financial Conference Schedule

GlobeNewswire

a year ago

SoundThinking Sets Upcoming Financial Conference Schedule

Insider Sell Alert: CFO Sonia Jain Sells 39,191 Shares of Cars.com Inc

GuruFocus.com

a year ago

Insider Sell Alert: CFO Sonia Jain Sells 39,191 Shares of Cars.com Inc

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

GlobeNewswire

a year ago

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease

GlobeNewswire

a year ago

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease

McEwen Mining Announces Flow-Through Financing

GlobeNewswire

a year ago

McEwen Mining Announces Flow-Through Financing

Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning

Investor's Business Daily

a year ago

Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning

Share on Social Networks: